Company Overview and News

32
EU mergers and takeovers (Oct 19)

2018-10-19 reuters
BRUSSELS, Oct 19 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
LBTY DTEGF WHR 500470 LBTYK LILAB KWR DIS DLELY AVOL AWI FOX SPR LBTYB LBTYA IDL SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA

8
Software AG (SWDAF) CEO Sanjay Brahmawar on Q3 2018 Results - Earnings Call Transcript

2018-10-19 seekingalpha
Ladies and gentlemen, thank you for standing by. I'm Stuart, your chorus call operator. Welcome, and thank you for joining the Software AG Release Q3 Results 2018 Conference Call. [Operation Instructions]
SWDAF DVMT KORS MS DTEGF DTEGY

 
Volkswagen a winner as EU set to favour wifi over 5G - draft

2018-10-19 channelnewsasia
BRUSSELS: The European Commission is set to approve and set rules for the use of wifi in cars, giving Volkswagen and Renault who have pursued this technology the edge over Daimler and others who invested in rival 5G networks.
KPSHF DTEGF DTEGY

 
Volkswagen a winner as EU set to favour wifi over 5G - draft

2018-10-19 reuters
BRUSSELS (Reuters) - The European Commission is set to approve and set rules for the use of wifi in cars, giving Volkswagen and Renault who have pursued this technology the edge over Daimler and others who invested in rival 5G networks.
KPSHF DTEGF DTEGY

 
European shares rebound from 22-month low

2018-10-16 thehindubusinessline
European shares rose on Tuesday helped by stronger defensive stocks as the focus turned to the start of the reporting season which is expected to deliver double-digit earnings growth for the third quarter.
BAESY SOUTHBANK 532218 BA DTEGF BAESF DTEGY

1
Clear Blue Technologies, Facebook, and Telefonica Announce OpenCellular-Power Progress at TIP Summit

2018-10-16 globenewswire
Speakers will share results of OpenCellular-Power projects as a part of the Telecom Infra Project’s reimagining of internet infrastructure
SKMD SKM DTEGF DTEGY

33
EU mergers and takeovers (Oct 15)

2018-10-15 reuters
BRUSSELS, Oct 15 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
4091 LBTY DTEGF WHR 500470 LBTYK LILAB DIS DLELY AVOL FOX SPR LBTYB LBTYA IDL CG SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA

33
EU mergers and takeovers (Oct 12)

2018-10-12 reuters
BRUSSELS, Oct 12 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
4091 LBTY HGKGF DTEGF WHR 500470 LBTYK LILAB DIS DLELY AVOL FOX SPR LBTYB LBTYA HGKGY IDL CG SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA

33
UPDATE 1-EU mergers and takeovers (Oct 11)

2018-10-11 reuters
BRUSSELS, Oct 11 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
4091 LBTY HGKGF DTEGF WHR 500470 LBTYK LILAB DIS DLELY AVOL FOX SPR LBTYB LBTYA HGKGY IDL CG SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA

33
UPDATE 1-EU mergers and takeovers (Oct 10)

2018-10-10 reuters
BRUSSELS, Oct 10 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
4091 LBTY HGKGF DTEGF WHR 500470 LBTYK LILAB DIS DLELY AVOL FOX SPR LBTYB LBTYA HGKGY IDL CG SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA

 
Deutsche Telekom to launch commercial 5G operations in 2020

2018-10-10 channelnewsasia
Deutsche Telekom will launch commercial 5G operations in Germany in 2020, as long as enough commercial devices are available, Chief Executive Tim Hoettges said on Wednesday as he pledged to keep up the pace of network investments.
DTEGF DTEGY

 
Albania wants to block entry of Serbian mobile phone company

2018-10-09 nzherald.co.nz
TIRANA, Albania (AP) — The Albanian government says it is against the takeover of the country's second-biggest mobile phone company by a Serbian counterpart.
DTEGF DTEGY

18
Deals of the day-Mergers and acquisitions

2018-10-08 reuters
Oct 8 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:
GEC GE RPC RPCGY BNPQY BNNCY BNPQF DTEGF APO RPCGF BNPZY BHI ESV PUK 0700 GNE MYO DTEGY PUKPF

32
EU mergers and takeovers (Oct 8)

2018-10-08 reuters
BRUSSELS, Oct 8 (Reuters) - The following are mergers under review by the European Commission and a brief guide to the EU merger process:
4091 LBTY HGKGF DTEGF 500470 LBTYK LILAB DIS DLELY AVOL FOX SPR LBTYB LBTYA HGKGY IDL CG SNEJF BKNG TTST TATASTEEL TATLY LILAK SNE MSFT HPQ FOXA DTEGY LILA

 
Anoto ingår nytt kommersiellt kontrakt med Deutsche Telekom

2018-10-08 globenewswire
Stockholm, den 8 oktober 2018 – Anoto Group AB (Anoto) meddelar idag att bolaget har undertecknat ett treårigt licensavtal med Deutsche Telekom IT GmbH (Deutsche Telekom). Avtalet återupprättar ramverket, inom vilket Anoto och Deutsche Telekoms kommer att samarbeta för att tillgodose behoven hos Deutsche Telekoms organisationskunder. Deutsche Telekom är en av de största kunderna när det gäller årlig mönsteranvändning, vilket motsvarar mer än 100 miljoner unika mönstersidor per år.
AOTTF AOTOF DTEGF DTEGY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...